Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sodium phenylacetate/sodium benzoate - Bausch Health Companies

Drug Profile

Sodium phenylacetate/sodium benzoate - Bausch Health Companies

Alternative Names: AMMONUL; Sodium benzoate/sodium phenylacetate; TAK-123

Latest Information Update: 06 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ucyclyd Pharma
  • Developer Hyperion Therapeutics; Ucyclyd Pharma
  • Class Benzoates; Esters; Hepatoprotectants; Neuroprotectants; Phenylacetates; Small molecules; Sodium compounds
  • Mechanism of Action Ammonia scavengers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatic encephalopathy; Hyperammonaemia
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hyperammonaemia
  • Discontinued Hepatic encephalopathy

Most Recent Events

  • 07 Nov 2019 Takeda plans a phase I pharmacokinetic trial (In volunteers) in Japan (IV, Infusion) , (NCT04155567)
  • 13 Jul 2018 Valeant Pharmaceuticals International is now called Bausch Health Companies
  • 02 May 2018 9238863: Created and added deal 25994, Updated Org table and HE; Updated Dev table for registered in Europe
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top